Open AccessEffect of levetiracetam usage on serum creatine phosphokinase concentration in patients with epilepsy
Author(s) -
Faruk Incecık,
Özlem Hergüner,
Şeyda Beşen
Publication year - 2020
Publication title -
journal of pediatric neurosciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.247
H-Index - 18
eISSN - 1998-3948
pISSN - 1817-1745
DOI - 10.4103/jpn.jpn_133_18
Subject(s) - medicine , rhabdomyolysis , levetiracetam , creatine kinase , epilepsy , somnolence , anesthesia , adverse effect , antiepileptic drug , pediatrics , gastroenterology , psychiatry
Levetiracetam (LEV) is a widely used antiepileptic drug (AED) in the treatment of various type of seizures, including generalized epileptic seizure as well as focal seizures, and it is generally well tolerated. Common side effects of LEV are somnolence, asthenia, dizziness, mood changes, kidney dysfunction, minor infections, and thrombocytopenia. Recently, increased creatine phosphokinase (CPK) concentration or rhabdomyolysis after LEV administration has been reported. The goal of the study was to evaluate clinical risk factors associated with increased CPK concentration or rhabdomyolysis in LEV administration.